{"name":"Eiger BioPharmaceuticals","slug":"eiger","ticker":"EIGR","exchange":"NASDAQ","domain":"eigerbio.com","description":"Eiger BioPharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases and virology. The company's pipeline includes several promising candidates, including peginterferon lambda for the treatment of hepatitis delta virus (HDV) infection. Eiger has established a strong presence in the rare disease and virology markets, with a growing portfolio of products and a commitment to innovation. As a result, the company is well-positioned for continued growth and success in the years to come.","hq":"Palo Alto, CA","founded":0,"employees":"","ceo":"David Cory","sector":"Rare Disease / Virology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":28000000,"revenueGrowth":17,"grossMargin":0,"rdSpend":62331000,"netIncome":-74963000,"cash":38826000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Peginterferon Lambda patent cliff ($100M at risk)","drug":"Peginterferon Lambda","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo Lonafarnib","genericName":"Placebo Lonafarnib","slug":"placebo-lonafarnib","indication":"KRAS-mutant pancreatic cancer","status":"phase_3"}]}],"pipeline":[{"name":"Placebo Lonafarnib","genericName":"Placebo Lonafarnib","slug":"placebo-lonafarnib","phase":"phase_3","mechanism":"Lonafarnib inhibits farnesyltransferase, blocking the post-translational modification of proteins involved in cell proliferation and survival.","indications":["KRAS-mutant pancreatic cancer","HRAS-mutant head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Eiger reported fourth quarter and full year 2023 financial results, with net product revenue of $24.4 million and a net loss of $34.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Eiger BioPharmaceuticals Announces Collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to Develop a Novel Treatment for Hepatitis B Virus (HBV) Infection","summary":"Eiger announced a collaboration with NIAID to develop a novel treatment for HBV infection, with the goal of advancing a new therapeutic candidate into clinical trials.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Eiger BioPharmaceuticals Receives FDA Approval for Expanded Use of Peginterferon Lambda for the Treatment of Hepatitis Delta Virus (HDV) Infection","summary":"Eiger announced that the FDA had approved an expanded indication for peginterferon lambda for the treatment of HDV infection, allowing for the use of the therapy in patients with chronic hepatitis B virus (HBV) infection.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2024-10-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-09-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-09-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-09-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-08-26","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2024-08-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-08-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-07-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-07-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-07-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-06-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-06-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-05-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-05-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-05-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"Peginterferon Lambda","drugSlug":"peginterferon-lambda","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Merck & Co.","Bristol-Myers Squibb"],"therapeuticFocus":["Rare Diseases","Virology"],"financials":{"source":"sec_edgar+yahoo","revenue":15773000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":15773000,"period":"2023-12-31"},{"value":13484000,"period":"2022-12-31"},{"value":13484000,"period":"2022-12-31"},{"value":12142000,"period":"2021-12-31"},{"value":12142000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":62331000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-74963000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":38826000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}